Rani Therapeutics Holdings, Inc. Class A Share Price
NASDAQ: RANI | Micro CapRani Therapeutics Holdings, Inc. Class A Stock Performance
Open $0.85 | Prev. Close $0.85 | Circuit Range N/A |
Day Range $0.84 - $0.85 | Year Range $0.44 - $3.85 | Volume 2,432 |
Average Traded $0.84 |
Rani Therapeutics Holdings, Inc. Class A Share Price Today
As of 31 August 2026, Rani Therapeutics Holdings, Inc. Class A's share price is $0.85. The stock opened at $0.85, compared to its previous close of $0.85. During today's trading session, Rani Therapeutics Holdings, Inc. Class A's share price traded between $0.84 and $0.85, with an average price of $0.85. Over the past 52 weeks, the stock has recorded a high of $3.85 and a low of $0.44. In terms of performance, Rani Therapeutics Holdings, Inc. Class A's share price has declined by 38.76% over the last six months and is up 65.71% on a year-on-year basis.
Rani Therapeutics Holdings, Inc. Class A Share Price Chart
Rani Therapeutics Holdings, Inc. Class A Stock Fundamentals & Key Indicators
Market Cap $55893.22 | PE Ratio (TTM) -1.88 | Dividend Yield N/A |
EPS (TTM) $-0.45 | Revenue (TTM) $1.63M | Return On Equity (TTM) -124.05% |
Profit Margin -2507.65% | Debt to Equity 0.38 | Quarterly Earnings Growth YoY N/A |
Rani Therapeutics Holdings, Inc. Class A Quarterly Profit & Loss
All figures in USD
About Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Rani Therapeutics Holdings, Inc. Class A Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $0.80 | $0.85 | +9.51% |
Jul 2026 | $0.77 | $0.78 | +2.23% |
Jun 2026 | $0.94 | $0.76 | -19.98% |
May 2026 | $0.91 | $0.95 | +7.46% |
Apr 2026 | $0.73 | $0.89 | +21.57% |
Mar 2026 | $1.34 | $0.73 | -47.25% |
Feb 2026 | $1.20 | $1.38 | +15.00% |
Jan 2026 | $1.37 | $1.20 | -11.44% |
Dec 2025 | $1.55 | $1.35 | -14.78% |
Nov 2025 | $2.42 | $1.59 | -27.06% |
Oct 2025 | $0.50 | $2.18 | +338.63% |
Sep 2025 | $0.49 | $0.50 | -2.55% |
RANI Share Price FAQs
What is Rani Therapeutics Holdings, Inc. Class A share price today?
What is the 52 week high and 52 week low of Rani Therapeutics Holdings, Inc. Class A stock?
What is RANI's market capitalisation today?
What is RANI's net income for the last quarter?
What is the 5 year returns of RANI?
What is the high & low stock price of RANI today?
Can I buy RANI shares in India?